Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-2 of 2
Keywords: Sustained-release alfuzosin
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Further Areas
Journal:
European Urology
European Urology (1997) 31 (2): 190–198.
Published Online: 11 August 2017
... is an effective treatment of symptoms related to BPH that shows a good safety profile in normotensive and hypertensive patients, without the need of dose titration. Sustained-release alfuzosin α(1)-Blockers Benign prostatic hyperplasia 11 8 2017 1997 Copyright / Drug Dosage / Disclaimer...
Journal Articles
Subject Area:
Further Areas
F.M.J. Debruyne, A. Jardin, D. Colloi, L. Resel, W.P.J. Witjes, M.C. Delauche-Cavallier, C. McCarthy, C. Geffriaud-Ricouard
Journal:
European Urology
European Urology (1998) 34 (3): 169–175.
Published Online: 02 September 1998
..., block the conversion of testosterone to dihyrotestosterone, resulting in a reduction in prostate volume. The efficacy of this therapy is delayed, taking at least 3 months to be achieved [ 4, 5, 8 ]. Benign prostatic hyperplasia Sustained-release alfuzosin α 1 -Blockers Finasteride 5α-Reductase...